Key Points
- Director Brian Posner bought 2,000 shares of Dyne Therapeutics at $18.21 each, a $36,420 transaction that raised his direct stake to 20,000 shares.
- Dyne Therapeutics recently reported quarterly earnings of ($0.73) per share, beating analyst estimates of ($0.77), while analysts still expect the company to post a full-year loss.
- Wall Street sentiment remains mostly positive, with a Moderate Buy consensus and a $35.00 average price target, even as the stock trades near $18.56 and the company continues developing therapies for rare muscle diseases.
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Brian Posner acquired 2,000 shares of the business's stock in a transaction that occurred on Tuesday, May 26th. The shares were purchased at an average cost of $18.21 per share, for a total transaction of $36,420.00. Following the completion of the transaction, the director directly owned 20,000 shares in the company, valued at $364,200. The trade was a 11.11% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Dyne Therapeutics Stock Performance
Shares of DYN stock opened at $18.56 on Friday. Dyne Therapeutics, Inc. has a one year low of $8.06 and a one year high of $25.00. The company's 50-day moving average is $18.27 and its 200 day moving average is $18.31. The company has a market capitalization of $3.07 billion, a price-to-earnings ratio of -5.76 and a beta of 1.08. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating analysts' consensus estimates of ($0.77) by $0.04. During the same quarter in the previous year, the firm posted ($1.05) EPS. Sell-side analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.
Institutional Investors Weigh In On Dyne Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. boosted its holdings in Dyne Therapeutics by 523.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock worth $343,085,000 after purchasing an additional 14,727,667 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Dyne Therapeutics by 14.9% in the fourth quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company's stock worth $219,376,000 after purchasing an additional 1,455,151 shares during the last quarter. State Street Corp boosted its holdings in Dyne Therapeutics by 27.0% in the fourth quarter. State Street Corp now owns 6,692,745 shares of the company's stock worth $130,910,000 after purchasing an additional 1,423,828 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in Dyne Therapeutics by 45.5% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company's stock worth $101,164,000 after purchasing an additional 1,618,000 shares during the last quarter. Finally, Orbis Allan Gray Ltd purchased a new stake in Dyne Therapeutics in the fourth quarter worth approximately $93,926,000. Hedge funds and other institutional investors own 96.68% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently commented on the stock. Wall Street Zen upgraded shares of Dyne Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, May 16th. Chardan Capital reiterated a "buy" rating and set a $38.00 price target on shares of Dyne Therapeutics in a report on Monday, March 9th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Evercore set a $33.00 price objective on Dyne Therapeutics in a research report on Friday, May 15th. Finally, Sanford C. Bernstein increased their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a "market perform" rating in a research report on Wednesday, May 13th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.00.
View Our Latest Report on Dyne Therapeutics
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
